EchoiQ

ASX: EIQ **1 September 2026**

Global healthcare investment leader appointed to Board

- **Mr Scott Wilkin appointed as a Non-Executive Director, effective 1 September 2026**
- **Mr Wilkin has ~35 years' experience across global equity markets with a distinct focus on the broader healthcare sector**
- **Mr Wilkin recently retired from UBS Asset Management, where he served as Co-Head of Global Equity, overseeing US$30 billion in assets under management**
- **Deep healthcare expertise, including more than a decade as an institutional research analyst covering medical technology, diagnostics and cardiovascular markets**
- **Brings an extensive global network across the healthcare, medical technology and investment sectors**
- **Appointment strengthens Board as the Company accelerates US commercialisation**

Sydney: AI and Medical Technology company Echo IQ ("the Company" or "Echo IQ") (ASX) is pleased to announce the appointment of highly experienced global healthcare investor and former medical technology analyst Mr Scott Wilkin as a Non-Executive Director, effective 1 September 2026.

Mr Wilkin brings 35 years of global investment and healthcare sector experience to Echo IQ. Prior to retirement, he served as Co-Head of Global Equity at UBS Asset Management, where he led its global equity business with over US$30Bn in assets under management.

His appointment further strengthens Echo IQ's Board as the Company advances the commercialisation of the EchoSolv suite across the US and other international markets.

Earlier in his career, Mr Wilkin spent more than a decade as an institutional research analyst specialising in medical technology and healthcare. He served as Managing Director of Medical Technology Institutional Research at SG Cowen Securities and Director of Medical Technology Institutional Research at UBS Warburg, covering the medical technology, diagnostics, hospital supply, laboratory equipment and cardiovascular sectors.

This experience provided Mr Wilkin with extensive exposure to the development and commercialisation of new healthcare technologies, including the pathways through which diagnostic and cardiovascular technologies achieve clinical adoption and reimbursement in the US.

Over his career, he has also developed an extensive global network across the healthcare, medical technology and investment sectors and engaged directly with the management teams of leading healthcare companies globally. The Company expects to leverage this network and Mr Wilkin's deep industry experience to support its US commercialisation strategy, including engagement with healthcare systems, strategic partners and other industry participants as Echo IQ scales its technology across the US market.

Mr Wilkin holds an MBA from Harvard Business School and a Bachelor of Arts in Biochemistry, with a minor in Economics, from Bowdoin College.

Management commentary:

Executive Chair, Mr Andrew Grover, said: *"Scott's appointment is highly complementary to the next phase of Echo IQ's growth. He brings 35 years of experience across global healthcare investment and equity markets, together with deep knowledge of the medical technology, diagnostics and cardiovascular sectors.*

Importantly, Scott understands how new diagnostic technologies move from clinical validation through to adoption and reimbursement in the US. That experience, combined with his extensive relationships across the global healthcare and investment communities, will be highly valuable as we continue to scale commercially. We are delighted to welcome Scott to the Board at this important stage in the Company's development."

Incoming Non-Executive Director, Mr Scott Wilkin said: *"Echo IQ is entering an exciting stage of its development as it seeks to translate differentiated cardiac technology into broader clinical adoption.*

Having spent much of my career analysing and investing in healthcare and medical technology companies globally, I have seen the value that differentiated diagnostic technologies can create when they address significant unmet clinical needs and are successfully integrated into clinical practice.

I am pleased to join the Echo IQ Board and look forward to working with Andrew, Dustin, the Board and management team as the Company continues to build its presence in the United States and other key international markets."

- ENDS -

Authorised for release by the Board of Directors of Echo IQ Limited.

Investor Enquiries:

Andrew Grover, Executive Chair
Andrew.grover@echoiq.ai / investor@echoiq.ai

Henry Jordan, Six Degrees Investor Relations
Henry.jordan@sdir.com.au / +61 (0) 431 271 538

ABOUT ECHO IQ

Echo IQ uses AI-driven technology and proprietary software to improve decision making in Cardiology. The company is based in Sydney, Australia.